Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISTOTLE: Standard versus novel chemoradiotherapy as pre-operative treatment for MRI-defined locally advanced rectal cancer
2008-005782-59Phase 3Unknown
- Sponsor
- University College London
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan and capecitabine in rectal cancer (2 arms), sponsored by University College London. Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
irinotecancapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2008-005782-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005782-59.